贝达药业(300558) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥735,775,468.80, representing a 38.40% increase compared to ¥531,618,547.85 in the same period last year[5] - Net profit attributable to shareholders was ¥98,140,741.56, a significant increase of 90.95% from ¥51,396,813.71 year-over-year[5] - The net profit after deducting non-recurring gains and losses surged by 390.39% to ¥89,562,834.38, compared to ¥18,263,590.71 in the previous year[5] - Basic and diluted earnings per share both rose to ¥0.23, reflecting a 91.67% increase from ¥0.12[5] - Operating profit for the quarter was ¥108,359,629.25, compared to ¥4,863,487.35 in Q1 2023, indicating a substantial improvement[20] - The company reported a total comprehensive income of ¥241,283,970.75, significantly higher than ¥11,728,582.69 in the previous year[21] Cash Flow and Assets - Operating cash flow net amount increased by 79.12% to ¥247,235,603.12, up from ¥138,024,453.30 in the same quarter last year[5] - Cash inflow from operating activities totaled ¥868,051,394.75, an increase from ¥675,281,814.25 in Q1 2023[22] - Total current assets decreased from CNY 1,525,880,626.51 to CNY 1,291,522,377.58, a reduction of approximately 15.3%[18] - Cash and cash equivalents decreased from CNY 751,996,914.50 to CNY 554,020,499.69, a decline of about 26.3%[18] - Total assets at the end of the reporting period were ¥9,326,460,058.88, a 1.96% increase from ¥9,146,908,395.53 at the end of the previous year[5] - The cash inflow from financing activities was 308,600,000.00 CNY, significantly lower than 1,138,995,335.39 CNY in the previous year, a decrease of about 72.9%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,919, with the top ten shareholders holding significant stakes[8] - Shareholders' equity attributable to the parent company increased by 5.16% to ¥5,522,175,127.32 from ¥5,251,077,081.90[5] - The company’s major shareholders include Ningbo Kaiming Investment Management Partnership, holding 80,064,000 shares, which is 21.74% of the total shares[10] Research and Development - R&D investment for Q1 2024 was 209.30 million RMB, accounting for 28.44% of operating revenue[13] - The company received FDA acceptance for the market application of its drug, Baimena, which is expected to be the first lung cancer targeted innovative drug developed by a Chinese pharmaceutical company to be launched globally[14] - Clinical trial approval notifications were received for the Pan-EGFR inhibitor BPI-520105 and the IDH1/IDH2 dual inhibitor BPI-221351[14] - The company is actively monitoring the progress of EYP-1901's clinical research abroad and coordinating domestic clinical research efforts[15] - EYP-1901 shows promising future treatment potential for wet AMD, with ongoing clinical trials for NPDR and DME[15] Operational Strategy - The company continues to optimize operations based on market competition and business development needs[13] - The company plans to continue its new drug development projects and market expansion strategies[13] - The company has ongoing strategic collaborations and investments, including the introduction of project CFT8919[17] Liabilities and Expenses - Total liabilities decreased from CNY 3,795,434,736.73 to CNY 3,713,620,126.31, a reduction of approximately 2.2%[19] - Sales expenses rose by 49.54% to ¥230,482,714.67, primarily due to increased costs associated with new product promotions[7] - Research and development expenses were ¥152,750,433.40, a decrease of 12.9% from ¥175,355,803.09 in the previous year[20] - The total cash outflow for employee compensation was 213,183,145.78 CNY, up from 199,114,465.21 CNY, marking an increase of approximately 7.4%[23] - The company paid taxes amounting to 25,301,455.53 CNY, which is an increase from 15,855,962.13 CNY, representing a growth of about 59.5%[23]